Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study.

BACKGROUND

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with skin barrier disruptions and heightened T helper (Th) 2-mediated inflammation. Dupilumab, a monoclonal antibody targeting interleukin-4 and -13 pathways, has shown efficacy in treating AD and other type 2 inflammatory diseases. However, its safety and effectiveness in special populations (SP) like kidney transplant recipients, cancer patients, and individuals with neurological conditions remain unclear.

MATERIALS AND

METHODS

This retrospective case series includes 12 representative cases of SP treated with dupilumab, featuring cases of a kidney transplant recipient, a metastatic melanoma patient, a non-functioning pituitary adenoma patient, and an individual with multiple sclerosis (MS). Clinical data were collected, and outcomes were assessed using various indices.

RESULTS

Dupilumab provided significant AD symptom improvement across all cases, with no adverse effects or recurrence of underlying conditions.

CONCLUSION

Dupilumab shows promise for managing AD in SP, but careful monitoring and further research are necessary to address safety concerns and optimize treatment strategies. Larger studies with longer follow-ups are needed to fully evaluate its safety and efficacy in SP and those with comorbidities. These findings support the need for personalized treatments and ongoing research to enhance outcomes in patients with complex medical histories.